vétoquinol sa - VETOF

VETOF

Close Chg Chg %
77.91 9.60 12.32%

Pre-Market

87.51

+9.60 (12.32%)

Volume: 100.00

Last Updated:

Mar 21, 2025, 9:40 AM EDT

Company Overview: vétoquinol sa - VETOF

VETOF Key Data

Open

$87.51

Day Range

87.51 - 87.51

52 Week Range

N/A - N/A

Market Cap

N/A

Shares Outstanding

11.83M

Public Float

3.86M

Beta

67,652.60

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

N/A

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

 

VETOF Performance

No Data Available

VETOF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About vétoquinol sa - VETOF

Vétoquinol SA operates as a global animal health company. It supplies drugs and nonmedicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. The firm designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. It also manufactures antibiotic, anti-inflammatory, cardiology, and nephrology drugs. The company was founded by Joseph Frechin in 1933 and is headquartered in Lure, France.

VETOF At a Glance

Vétoquinol SA
34, rue du Chêne Sainte-Anne
Lure, Bourgogne-Franche-Comte 70200
Phone 33-3-84-62-55-55 Revenue 583.25M
Industry Pharmaceuticals: Major Net Income 63.50M
Sector Health Technology 2024 Sales Growth 1.93%
Fiscal Year-end 12 / 2025 Employees 2,501
View SEC Filings

VETOF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

VETOF Efficiency

Revenue/Employee 233,205.78
Income Per Employee 25,387.944
Receivables Turnover N/A
Total Asset Turnover N/A

VETOF Liquidity

Current Ratio N/A
Quick Ratio N/A
Cash Ratio N/A

VETOF Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin 10.886
Return on Assets N/A
Return on Equity N/A
Return on Total Capital N/A
Return on Invested Capital N/A

VETOF Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Vétoquinol Sa - VETOF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
616.13M 567.29M 572.20M 583.25M
Sales Growth
+26.44% -7.93% +0.87% +1.93%
Cost of Goods Sold (COGS) incl D&A
- 418.30M 386.14M 401.29M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 38.85M 33.16M 34.19M
Depreciation
- 18.17M 16.39M 18.32M
Amortization of Intangibles
- 20.68M 16.77M 15.87M
COGS Growth
- +20.91% -7.69% +3.92%
Gross Income
- 197.83M 181.15M 170.92M
Gross Income Growth
- +39.98% -8.43% -5.65%
Gross Profit Margin
- +32.11% +31.93% +29.87%
2021 2022 2023 2024 5-year trend
SG&A Expense
- 100.43M 89.50M 88.54M
Research & Development
- 36.64M 26.27M 32.76M
Other SG&A
- 63.79M 63.22M 55.78M
SGA Growth
- +36.44% -10.88% -1.07%
Other Operating Expense
- 6.07M 8.30M 11.34M
Unusual Expense
- (4.16M) 11.09M 3.86M
EBIT after Unusual Expense
- 95.49M 72.27M 67.18M
Non Operating Income/Expense
- 3.78M 3.30M 11.69M
Non-Operating Interest Income
- 432.61K 848.14K 3.54M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 1.22M 3.43M 1.23M
Interest Expense Growth
- -0.26% +179.88% -64.13%
Gross Interest Expense
- 1.22M 3.43M 1.23M
Interest Capitalized
- - - -
-
Pretax Income
- 98.04M 72.15M 77.64M
Pretax Income Growth
- +165.98% -26.41% +7.62%
Pretax Margin
- +15.91% +12.72% +13.57%
Income Tax
- 23.89M 21.70M 17.57M
Income Tax - Current - Domestic
- 31.69M 25.31M 21.94M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (3.59M) 697.85K 1.13M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- 4.21M 4.30M 5.50M
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
74.31M 50.44M 60.07M 63.50M
Minority Interest Expense
- 9.46K 3.15K 6.49K
Net Income
74.30M 50.44M 60.07M 63.50M
Net Income Growth
+239.09% -32.11% +19.08% +5.71%
Net Margin Growth
+12.06% +8.89% +10.50% +10.89%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
74.30M 50.44M 60.07M 63.50M
Preferred Dividends
- - - -
-
Net Income Available to Common
74.30M 50.44M 60.07M 63.50M
EPS (Basic)
6.2819 4.2633 5.0764 5.3439
EPS (Basic) Growth
+239.05% -32.13% +19.07% +5.27%
Basic Shares Outstanding
- 11.83M 11.83M 11.83M
EPS (Diluted)
- 6.2819 4.2633 5.0764
EPS (Diluted) Growth
- +239.05% -32.13% +19.07%
Diluted Shares Outstanding
- 11.83M 11.83M 11.83M
EBITDA
- 130.19M 116.52M 105.23M
EBITDA Growth
- +45.72% -10.50% -9.68%
EBITDA Margin
- +21.13% +20.54% +18.39%

VéToquinol Sa in the News